title: Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.
authors.forename: V
authors.initials: V
authors.lastname: Modesti
authors.forename: R
authors.initials: R
authors.lastname: Ramonda
authors.forename: A
authors.initials: A
authors.lastname: Ortolan
authors.forename: M
authors.initials: M
authors.lastname: Lorenzin
authors.forename: A
authors.initials: A
authors.lastname: Lo Nigro
authors.forename: P
authors.initials: P
authors.lastname: Frallonardo
authors.forename: F
authors.initials: F
authors.lastname: Oliviero
authors.forename: C
authors.initials: C
authors.lastname: Campana
authors.forename: L
authors.initials: L
authors.lastname: Punzi
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007239:Infections / Q000209:etiology*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012008:Recurrence; D012720:Severity of Illness Index; D025241:Spondylarthritis / Q000150:complications / Q000188:drug therapy*; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept